Kestra Advisory Services, LLC Corbus Pharmaceuticals Holdings, Inc. Transaction History

Kestra Advisory Services, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 31, 2023	BUY	$0.11 - $5.46 $170 - $8,463	1,550 Added 10.16%	16,800 $1,000
Q2 2022 Aug 12, 2022	SELL	$0.21 - $0.53 $105 - $265	-500 Reduced 3.17%	15,250 $4,000
Q1 2022 Apr 26, 2022	SELL	$0.32 - $0.67 $1,120 - $2,345	-3,500 Reduced 18.18%	15,750 $8,000
Q4 2021 Jan 20, 2022	SELL	$0.6 - $1.11 $2,604 - $4,817	-4,340 Reduced 18.4%	19,250 $11,000
Q3 2021 Oct 19, 2021	BUY	$1.01 - $1.82 $2,020 - $3,640	2,000 Added 9.26%	23,590 $24,000
Q2 2021 Jul 28, 2021	SELL	$1.39 - $2.21 $2,752 - $4,375	-1,980 Reduced 8.4%	21,590 $39,000
Q1 2021 May 10, 2021	SELL	$1.27 - $3.42 $5,295 - $14,261	-4,170 Reduced 15.03%	23,570 $46,000
Q4 2020 Jan 20, 2021	SELL	$0.94 - $1.89 $6,232 - $12,530	-6,630 Reduced 19.29%	27,740 $36 Million
Q3 2020 Nov 12, 2020	BUY	$1.5 - $9.38 $51,555 - $322,390	34,370 New	34,370 $62 Million

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $1.22B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Kestra Advisory Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Kestra Advisory Services, LLC with notifications on news.